How much does a box of brivaracetam tablets cost and market price trends

Brivaracetam (Brivaracetam) is an anti-epileptic drug used to treat epilepsy. It belongs to a new generation of selective synaptic vesicle protein 2A (SV2A) ligand. It has a similar mechanism of action to levetiracetam but has stronger affinity. This drug is commonly used as an auxiliary treatment for partial seizures in adults and adolescents with epilepsy. In recent years, with the growing global demand for precise epilepsy treatment, brivaracetam has gradually gained more attention, especially in European and American countries, where its clinical application has become relatively mature.

Currently, Brivaracetam has not been officially launched in mainland China, and domestic patients are temporarily unable to purchase the drug through regular pharmacy channels. However, in overseas markets, the original drug of Brivaracetam has been on the market for many years, and the more common specification is 50mg*60 tablets. It is understood that the price of this specification in the European and American markets is approximately 4,000 RMB. The actual price may fluctuate slightly due to factors such as purchasing channels, national taxes, and freight. Therefore, domestic patients in need of medicines can only purchase them through overseas medical platforms or cross-border drug purchase services.

Judging from the market price trend, as a new anti-epileptic drug, the price of brivaracetam was relatively high in the initial stage of marketing. However, as the number of countries on the market gradually increased and production costs were gradually optimized, its price has generally stabilized. Although the price is still high, it has been included in the medical insurance system in some countries, reducing the burden on patients to a certain extent. In areas that are not covered by medical insurance or need to pay for it at their own expense, patients still face certain financial pressure.

Overall, brivaracetam has received good clinical feedback in the international market, has relatively few side effects, and is considered a safe and effective auxiliary treatment option for epilepsy. If it can be approved for marketing in China in the future and supported by medical insurance policies, it will greatly improve the treatment options and burdens of epilepsy patients in my country. At present, it is still a prudent approach for patients to pay attention to drug launch trends and obtain medication recommendations from authoritative medical channels.

Reference materials:https://www.drugs.com/